A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.
about
Antibody-drug conjugates--an emerging class of cancer treatmentThe alternative splicing factor Nova2 regulates vascular development and lumen formation.Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranosticsUpregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugatePhotodynamic tumor eradication with a novel targetable photosensitizer: strong vascular effects and dependence on treatment repetition versus potentiation.Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable LinkerA HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150GluedMechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosisCirculating fibronectin controls tumor growthPhotonanomedicine: a convergence of photodynamic therapy and nanotechnology.Antibody-guided photoablation of voltage-gated potassium currentsThe antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.Oncolytic virotherapyAntibodies armed with photosensitizers: from chemical synthesis to photobiological applications.Emerging formats for next-generation antibody drug conjugates.Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Tailored immunoconjugate therapy depending on a quantity of tumor stroma.Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agentsFibronectins containing extradomain A or B enhance osteoblast differentiation via distinct integrins.8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.Delivery of a hydrophobic phthalocyanine photosensitizer using PEGylated gold nanoparticle conjugates for the in vivo photodynamic therapy of amelanotic melanoma.F8-SIP mediated targeted photodynamic therapy leads to microvascular dysfunction and reduced glioma growth.Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculatureEmerging classes of armed antibody therapeutics against cancerSpacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculatureA Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer TherapyFucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format
P2860
Q26770312-060E8C4E-4A86-4E56-BD82-EE64324DBFC0Q27321847-05995CAB-980D-46BE-A618-C8D3D356BD00Q30462417-505D09C1-0E6B-43E5-8BB8-23FC90D86082Q33648759-DD48287A-0DEA-47DE-90D1-8FC2D47A9E7DQ34474855-13E445C1-BFC3-4667-BD5F-5B4243C199D0Q34663010-084A8160-E8E6-4BE6-A73D-92372F48B0ADQ36097775-DD0FD359-3741-4E52-B908-A4C0F23C7ACDQ36149661-50C8CD56-291D-42CA-89E4-467B236AF61EQ36451532-13580D82-CE90-4929-91BC-674C8AE5F0C2Q37061025-A95BA80F-4566-4247-9E72-4E8EF2369379Q37115994-7EBDD7A2-8C44-408B-9894-DF58983E5902Q37121994-E60E1985-4ECD-4A0F-880F-0974C0AA3E4FQ37185752-581277AC-6AE7-44A4-A5B5-3CBF6DEE5C87Q38025263-23647EDC-DF20-4DA1-BDAB-FB53FB240EE7Q38328583-80601D89-6D8E-467D-A016-19ED57AC4DC5Q38386705-D436DE99-71CC-42A5-8D03-FA123D7C9EA9Q38699434-B71EB47C-BB99-4C37-B73D-75A907C253B8Q38899910-8DE0FCF4-9731-4204-9861-06FE4F746A8EQ39100229-0EC0FC1F-AEE8-4C42-BCF5-D67B5FCFF11BQ39205186-C722E405-853F-4898-A6F9-BDB0F99E81D8Q39250458-C39FF233-28FD-426B-9A58-F9C52E7A6D62Q39310603-DD49D860-F2FB-4439-9987-AB3E622CF438Q42801853-F00745B8-38A3-440F-AFD7-5E9344F99B4FQ42906644-F5665859-EA38-4F0F-9B12-8422D9E44B4EQ46566008-6520F556-E6B3-4370-89A3-BB954371C97DQ48730267-57E7E712-0A14-4E6F-8CF1-F30B1BCDD772Q52704026-AF1955B2-0E93-4831-BE33-61644EEB9B7DQ55039208-FB21F169-76BE-4CAE-8FF8-83B9AEE2E9D2Q57072218-F345B510-5A01-40A0-B159-749EEEDFDD0EQ57911948-6A8AD063-3B69-40A6-974F-7377EECD59B4Q57911963-DE4DDD50-9901-48B2-89A5-4BA28C774DCDQ57911965-FA67226C-9689-4FF4-A13F-6E1C0BFE5CF4Q57911974-B1D57857-B241-4167-B4CF-39CD873C5447
P2860
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A chemically modified antibody ...... ption of tumour blood vessels.
@ast
A chemically modified antibody ...... ption of tumour blood vessels.
@en
A chemically modified antibody ...... ption of tumour blood vessels.
@nl
type
label
A chemically modified antibody ...... ption of tumour blood vessels.
@ast
A chemically modified antibody ...... ption of tumour blood vessels.
@en
A chemically modified antibody ...... ption of tumour blood vessels.
@nl
prefLabel
A chemically modified antibody ...... ption of tumour blood vessels.
@ast
A chemically modified antibody ...... ption of tumour blood vessels.
@en
A chemically modified antibody ...... ption of tumour blood vessels.
@nl
P2093
P2860
P356
P1476
A chemically modified antibody ...... ption of tumour blood vessels.
@en
P2093
A Soltermann
G F Hofbauer
K Schwager
P Dziunycz
P2860
P2888
P304
P356
10.1038/BJC.2011.78
P407
P50
P577
2011-03-08T00:00:00Z
P5875
P6179
1020004152